{
    "id": 25763,
    "fullName": "MAPK1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAPK1 positive indicates the presence of the MAPK1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5594,
        "geneSymbol": "MAPK1",
        "terms": [
            "MAPK1",
            "ERK",
            "ERK-2",
            "ERK2",
            "ERT1",
            "MAPK2",
            "p38",
            "p40",
            "p41",
            "p41mapk",
            "p42-MAPK",
            "P42MAPK",
            "PRKM1",
            "PRKM2"
        ]
    },
    "variant": "positive",
    "createDate": "11/28/2016",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9425,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, high phosphorylated Mapk1 level correlated with poor overall survival in high-grade serous ovarian cancer patients, suggesting Mapk1 hyperactivation may serve as a prognostic marker (PMID: 26482043).",
            "molecularProfile": {
                "id": 26841,
                "profileName": "MAPK1 positive"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7184,
                    "pubMedId": 26482043,
                    "title": "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482043"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9422,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) and Selumetinib (AZD6244) synergistically inhibited Mapk1 signaling, resulted in cell cycle arrest in ovarian serous carcinoma cells with high Esr1 expression and low Mapk1 activity in culture and tumor growth inhibition in cell line xenograft models (PMID: 26482043).",
            "molecularProfile": {
                "id": 26841,
                "profileName": "MAPK1 positive"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7184,
                    "pubMedId": 26482043,
                    "title": "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482043"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) and Selumetinib (AZD6244) synergistically inhibited survival of ER-positive ovarian serous carcinoma cells with high Mapk1 activity in culture (PMID: 26482043).",
            "molecularProfile": {
                "id": 26842,
                "profileName": "ESR1 pos MAPK1 pos"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7184,
                    "pubMedId": 26482043,
                    "title": "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482043"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9424,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ER-positive ovarian serous carcinoma cells with high Mapk1 activity were resistant to Selumetinib (AZD6244) in culture (PMID: 26482043).",
            "molecularProfile": {
                "id": 26842,
                "profileName": "ESR1 pos MAPK1 pos"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7184,
                    "pubMedId": 26482043,
                    "title": "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482043"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26841,
            "profileName": "MAPK1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26842,
            "profileName": "ESR1 pos MAPK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26843,
            "profileName": "ESR1 over exp MAPK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}